P300 modulation via transcranial alternating current stimulation in patients with attention deficit/hyperactivity disorder (ADHD)

Organizational Data

DRKS-ID:
DRKS00020828
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2020-05-04
Last update in DRKS:
2023-02-14
Registration type:
Prospective

Acronym/abbreviation of the study

P300-TACS

URL of the study

https://www.attention-projekt.de/

Brief summary in lay language

ADHD treatment in adults usually consists of drug and/or psychotherapeutic treatment, whereby the drug treatment success is usually higher than the psychotherapeutic treatment success. However, a drug-based ADHD treatment often leads to undesired side effects and must be closely monitored. The development of further, effective ADHD therapy approaches with few side effects therefore seems urgently indicated. The aim of the BMBF-funded project ATTENTION (= Mobile system for ADHD therapy using transcranial electrical neurostimulation) is the development of a novel medical-technical system for the targeted neuromodulation of attention-associated cortical networks by means of electrical stimulation. Specifically, a demonstrator will be developed with which attention-relevant EEG signals can be extracted and modulated by electrostimulation. Prior to this, this study will test whether neuromodulation by the brain stimulation method leads to attention enhancement in ADHD patients.

Brief summary in scientific language

Attention deficit hyperactivity disorder (ADHD) in adulthood is a common mental disorder with massive psychosocial and health-economical effects. ADHD treatment in adults usually consists of psychopharmacotherapeutic and/or psychotherapeutic treatment, whereby the psychopharma-cotherapeutic treatment success is usually higher than the psychotherapeutic treatment success. However, psychopharmacotherapeutic ADHD treatment often leads to undesirable side effects and must be closely monitored by physicians. In addition, in about 30% a psychopharmacothera-peutic treatment shows no effect or an intolerance. The development of further effective ADHD therapies with few side effects is therefore urgently indicated. Various studies analyzing data recorded by electroencephalography (EEG) examined event-related potentials (EKPs) in adult patients with ADHD and found a reduced P300 amplitude and prolonged latency compared to healthy subjects. Since P300 studies generally assume a connection between P300 amplitude and attention allocation, as well as between P300 latency and stimulus processing speed, an increase in P300 amplitude and a reduction in latency seems to be a promising therapeutic approach. Transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique, can increase the amplitude of endogenous brain oscillations. EKPs can be understood as event-related oscillations. The P300 component can thus be regarded as part of an oscillation in the delta (0-4Hz) to theta (4-8Hz) frequency range. The aim of the study is to increase the P300 amplitude in adult ADHD patients using tACS. In particular, the question that needs to be answered is whether, and if so, to what extent a tACS-based neuromodulation of attention-associated oscillatory networks (especially the delta rhythm and the P300 EKP component) leads to an improvement in attention in ADHD patients.

Health condition or problem studied

ICD10:
F90 - Hyperkinetic disorders
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
ADHD-Patients; Intervention vs. control-intervention (tACS-stimulation vs. Sham-stimulation). Each intervention will last approximately 60 minutes. With preparation and follow-up, a session will last no longer than 3 hours. The conditions (stimulation/sham) will be randomized so that one half of the ADHD patients will first receive the tACS-stimulation and the other half will first receive the sham-stimulation. In the second session, the conditions are then adjusted accordingly.
Arm 2:
Due to the limitations of the Corona pandemic, it was decided to conduct the study exclusively with ADHD patients and not to further include healthy controls for now.

Endpoints

Primary outcome:
Increase of the P300 amplitude by tACS (Measured by frequency analysis in the EEG).
Secondary outcome:
Improvement of attention performance (reaction times, omission and commission errors). Brain activity is measured by EEG before, during and after the interventions. The electrostimulation or sham stimulation will be applied with the help of a certified electrostimulator. The parameters for attention performance are measured by a visual oddball task (Comparison between before and after the intervention).

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Placebo
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
Yes
Assignment:
Crossover
Sequence generation:
No Entry
Who is blinded:
  • Patient/subject

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • Medical center Klinik und Poliklinik für Psychiatrie und Psychotherapie Bonn

Recruitment period and number of participants

Planned study start date:
2020-06-01
Actual study start date:
2020-07-28
Planned study completion date:
No Entry
Actual Study Completion Date:
2021-08-12
Target Sample Size:
25
Final Sample Size:
22

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
50 Years
Additional Inclusion Criteria:
Fulfilment of the diagnostic criteria for ADHD according to DSM-5 criteria, age between 18-50 years, normal or corrected vision, right-handed

Exclusion Criteria

Serious psychiatric disorders such as schizophrenia and/or affective disorders, antisocial personality disorder, current alcohol or drug addiction, serious organic diseases, epilepsy, seizure disorders (epilepsy) in the family, skin diseases/open spots on the head, metal in the brain/skull area, pregnancy, insufficient command of the German language

Addresses

Primary Sponsor

Address:
Klinik und Poliklinik für Psychiatrie und Psychotherapie Universitätsklinikum Bonn
Prof. Dr. Alexandra Philipsen
Venusberg Campus 1
53127 Bonn
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.ukbonn.de/42256BC8002AF3E7/direct/startseite-npp
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Klinik und Poliklinik für Psychiatrie und Psychotherapie Universitätsklinikum Bonn
Dr. Niclas Braun
Venusberg Campus 1
53127 Bonn
Germany
Telephone:
022828731374
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.ukbonn.de/42256BC8002AF3E7/direct/virtual-reality-therapy-and-psychophysiology

Contact for Public Queries

Address:
Uniklinikum Bonn
Kyra Kannen
Venusberg Campus 1
53127 Bonn
Germany
Telephone:
022828731291
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Klinik und Poliklinik für Psychiatrie und Psychotherapie Universitätsklinikum Bonn
Dr. Niclas Braun
Venusberg Campus 1
53127 Bonn
Germany
Telephone:
022828731374
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.ukbonn.de/42256BC8002AF3E7/direct/virtual-reality-therapy-and-psychophysiology

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)

Address:
Bundesministerium für Bildung und Forschung Dienstsitz Berlin
Friedrichstraße 130 B
10117 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.bmbf.de

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission Medizinische Fakultät Bonn
Venusberg Campus 1, Geb. 02
53105 Bonn
Germany
Telephone:
+49-228-28751282
Fax:
+49-228-28751932
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2019-10-01
Ethics committee number:
357/19
Vote of the Ethics Committee:
Approved
Date of the vote:
2020-01-08

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
The raw data will be provided by the authors, without inadequate reservations, 6 month after publication. On request, these will be made available to any qualified researcher.

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry